Status:
NOT_YET_RECRUITING
Open Label Clinical Trial of Intravenous Crotoxin Part 3
Lead Sponsor:
Celtic Biotech Ltd
Collaborating Sponsors:
Institut de Cancérologie de l'Ouest
Conditions:
Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
The primary objective of the study is to assess whether human subjects can be made tolerant to intravenously administered Crotoxin and achieve higher and more therapeutically effective doses levels wi...
Detailed Description
Crotoxin has been shown to induce neurotoxic tolerance in animals allowing them to receive high doses associated with effective anti-tumor activity in the absence of adverse side effects. The study p...
Eligibility Criteria
Inclusion
- Subjects will:
- Be adult patients with histologically confirmed advanced solid tumors (excluding basal cell, colon, pancreatic and stomach cancers) who have progressed despite standard therapy, or for whom no standard therapy exists.
- Have an ambulatory PS (ECOG 0-1).
- Have tumor evaluation made within 28 days before study drug administration
- Have completed radiotherapy or chemotherapy or any other anticancer therapy (including experimental therapy) more than 4 weeks prior to enrolment into the trial and must have recovered from all acute side effects of these treatments
- Have a life expectancy greater than 3 months
- Have an age ≥ 18 years
- Have normal marrow function with the following haematological parameters normal; Hb ≥10g/dl, WBC ≥4.0 x10E9/L, neutrophil count ≥ 2.0 x 10E9/L and platelets ≥100 x10E9 /L
- Have no medically significant impairment of cardiac or respiratory functions\<
- Have adequate hepatic function with Total bilirubin 1.5 x N and Transaminases \< 2.5 x N (\< 5 x N in case of liver metastasis).
- Have no history of prior severe allergic reactions to venoms
- Have Creatinine clearance \> 50 mL/min.
- Be on stable doses of any drugs which may affect hepatic drug metabolism or renal drug excretion (e.g.--non-steroidal anti-inflammatory drugs, barbiturates, narcotic analgesics, probenecid). Such drugs should not be initiated while the patient is participating in this study.
- Not be pregnant or planning to become pregnant
- Not known to have brain metastases or leptomeningeal involvement. CT-scan or MRI is not required to rule this out unless there is clinical suspicion of central nervous system involvement
- Not have pleural effusion/ ascites, cystic lesions or bone metastases, as the only assessable lesions
- Not have a history of other malignancies, except for patients with a cancer free interval of \> 5 years after treatment completion, patients with prior history of adequately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix
- Not have had recent major surgery (within 21 days).
- Not have a recent history of weight loss \> 10% of current body weight.
- Not have serious intermittent medical illnesses which would interfere with the ability of the patient to carry out the treatment program.
- Not be on chronic steroid medication (\> 20mg/day)
- Not have primary or paraneoplastic myasthenia gravis
- Be free of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule;
- Will agree to participate in the study prior to starting with any specific study procedure, after having signed written informed consent.
- Be patients of childbearing age willing to use contraceptive for the duration of the study
- Not live alone and live no further than approximately 30 km away from the hospital, and for the study duration have continuous access to the use of mobile telephone in case of medical emergency
Exclusion
Key Trial Info
Start Date :
August 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT01481532
Start Date
August 1 2024
End Date
December 1 2025
Last Update
January 17 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut de Cancérologie de l'Ouest
Saint-Herblain, France, 44805